Agios Sells Cancer Portfolio To Servier To Focus On Genetic Diseases

$2bn Deal With $1.8bn Up Front For Idhifa Rights, Tibsovo And More

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Agios’ cellular metabolism expertise first delivered cancer drugs but sees greater opportunity in genetically defined diseases. CEO Jackie Fouse talked to Scrip about the business strategy.

Business reengineering
Agios will focus entirely on genetic diseases after selling its cancer drugs

Agios Pharmaceuticals, Inc. and Les Laboratoires Servier SAS said on 21 December that they entered into a $2bn-plus agreement for the cellular metabolism specialist to sell its cancer drug portfolio to the private French pharmaceutical company so that Agios can focus on its pipeline of drugs for genetically defined diseases, led by the potential blockbuster mitapivat in hemolytic anemias.

Servier will pay Agios $1.8bn up front plus a $200m regulatory milestone fee tied to IDH1/2 inhibitor vorasidenib, a 5%...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.